Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

Medical IntelligenceFree PreviewArchive

Drug-Induced Restoration of Cutaneous Delayed Hypersensitivity in Anergic Patients with Cancer

List of authors.
  • Daniel Tripodi, Ph.D.,
  • Leon C. Parks, M.D.,
  • and Jo Brugmans, M.D.

NEOPLASTIC disease in man is often accompanied by defective cellular immunity as manifested by tests for cutaneous delayed hypersensitivity1 or by more sophisticated methods related to the ability of lymphocytes to react with target or tumor cells.2 Although it is unclear whether diminished immunocompetence precedes or is a result of advancing cancer, the high prevalence of neoplasia in congenital immune deficiency states, and in immunosuppressed transplant recipients,3 suggests that attenuated immunity contributes to the progression of malignant tumors. Patients with such tumors who remain responsive to delayed hypersensitivity testing have a more favorable prognosis than those who lack cellular immunity. . . .

Funding and Disclosures

We are indebted to Drs. G. M. Williams, W. Pollack and P. Janssen for encouragement and advice and to Mrs. Caroline Parks and Mr. Peter Levitch for technical assistance.

Author Affiliations

From the Department of Surgery, Johns Hopkins Hospital, Baltimore, Md. (address reprint requests to Dr. Tripodi at Ortho Research Foundation, Raritan, N.J. 08869).

Print Subscriber? Activate your online access.